Topical Minoxidil and Levothyroxine Interaction: What Patients and Clinicians Need to Know

Is there a direct interaction between topical minoxidil and levothyroxine?

None is documented. Minoxidil 2% and 5% solution and 5% foam are over-the-counter hair regrowth products [7]. The Drug Facts label does not name levothyroxine; using other medicines on the scalp is among the conditions listed in its warnings [1].

The levothyroxine interactions with a clear absorption mechanism are all oral. Calcium carbonate and ferrous sulfate bind levothyroxine and raise TSH when taken at the same time [2][3]. Reduced stomach acid, from omeprazole or chronic gastritis, raises the dose a patient needs [4].

One 2023 open-label study looked at acid suppression from another angle. It switched 47 thyroidectomized patients on a proton pump inhibitor from levothyroxine tablets to Tirosint soft capsules at the same dose. Among the 45 who completed, mean TSH fell by 0.32 mIU/L at 6 weeks and 0.68 mIU/L at 12 weeks. The study had no control group and was linked to the product's sponsor [8].

What actually changes levothyroxine absorption

Three studies show the size of these effects:

• Calcium carbonate. Twenty adults with hypothyroidism on stable levothyroxine took 1,200 mg/day of elemental calcium with their dose for 3 months. Mean TSH rose from 1.6 to 2.7 mIU/L and mean free T4 fell from 17 to 15 pmol/L, both returning toward baseline after calcium stopped. Twenty percent of patients had TSH above the normal range during the calcium period [2].
• Ferrous sulfate. Fourteen patients took a 300 mg ferrous sulfate tablet with their usual thyroxine daily for 12 weeks. Mean TSH rose from 1.6 to 5.4 mU/L (P<0.01), and nine patients had more symptoms and signs of hypothyroidism. The trial was uncontrolled [3].
• Stomach acid. In 248 patients with multinodular goiter, the thyroxine dose needed to reach a low TSH was 22% to 34% higher in those with H. pylori gastritis, atrophic gastritis or both than in 135 reference patients. In 10 patients on thyroxine who had reflux, omeprazole raised TSH in all of them, and a 37% thyroxine dose increase reversed it [4].

Levothyroxine labeling describes a single daily dose on an empty stomach, one-half to one hour before breakfast. It specifies at least four hours between levothyroxine and calcium carbonate or ferrous sulfate [9].

Do you need to time the two apart?

Neither label addresses the other product. Levothyroxine timing is set by its own labeling: empty stomach, one-half to one hour before breakfast, and four hours from calcium carbonate or ferrous sulfate [9]. The Tirosint oral solution is labeled for 15 minutes before breakfast instead [9]. Application is set by the minoxidil label: men's 5% solution as 1 mL twice daily to the scalp [1], and women's 5% foam as half a capful once daily [5].

What the labels say to watch for

The topical labels say to stop using the product if chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swelling of the hands or feet, scalp irritation or redness, or unwanted facial hair growth occurs [1][5]. Both labels carry a pre-use warning for people with heart disease [1][5]. The 5% solution is labeled flammable and the foam extremely flammable, with fire, flame and smoking to be avoided during and immediately after application [1][5].

Levothyroxine is a narrow-therapeutic-index drug. Its labeling warns about both under-replacement and over-replacement, with cardiac reactions a particular concern in older patients and in people with heart disease [9].

What about oral minoxidil?

Oral minoxidil tablets are a separate prescription product, approved for severe hypertension that is not manageable with a diuretic plus two other antihypertensive drugs [6]. Hair-loss use of the tablets is off-label. In a meta-analysis of uncontrolled studies using 5 mg/day or less for hair loss, systolic blood pressure changed by -0.13 mm Hg (95% CI -2.67 to 2.41) and heart rate rose 2.67 beats/min (95% CI 0.34 to 5.01). Hypotensive symptoms were reported in 119 patients (5.0%) [10]. A retrospective study of 1,404 patients with no control group reported lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9% [11].